Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

Phase 2 Completed 34 enrolled University of Nebraska National Cancer Institute (NCI) · collab Spectrum Pharmaceuticals, Inc · collab

NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well combination chemotherapy and pralatrexate works in treating patients with non-Hodgkin lymphoma (NHL). Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing

Timeline

Start: 2011-07-06
Primary completion: 2016-12-28
Completion: 2016-12-28

Publications

Background Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, Evens AM, Foss F, Horwitz S, Pro B, Pinter-Brown LC, Smith SM, Shustov AR, Savage KJ, Vose JM. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. Br J Haematol. 2016 Feb;172(4):535-44. doi: 10.1111/bjh.13855. Epub 2015 Dec 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	—	Intravenous
Subject	Etoposide	Small molecule	—	Oral
Subject	Pralatrexate	Other / unclassified	—	Intravenous
Subject	Prednisone	Other / unclassified	—	Oral
Subject	Vincristine	Small molecule	—	Intravenous

Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

Summary

Timeline

Publications

Drugs

Indications